RFA
PRVB

Reilly Financial Advisors’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

Reilly Financial Advisors’s Portfolio PRVB Stock Details PRVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		$1K Buy
+200
New +$1.27K ﹤0.01% 1111
2021
Q3 		– Sell
-200
Closed -$2K – 1094
2021
Q2 		$2K Hold
200
– – ﹤0.01% 938
2021
Q1 		$2K Buy
+200
New +$2.81K ﹤0.01% 961

Other funds holding PRVB

SC
Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
DCM
DG Capital Management New York $326M AUM 39.67% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Reilly Financial Advisors's PRVB Position: Q4 2021 in Review

Reilly Financial Advisors opened a new position in Provention Bio, Inc. Common Stock (PRVB) in Q4 2021: 200 shares worth $1K. The stake represents ﹤0.01% of the portfolio and ranks #1111 among its holdings. This is a return to the name: Reilly Financial Advisors previously reported a position in PRVB as recently as Q2 2021.

Reilly Financial Advisors first reported a position in PRVB in Q1 2021 and has held it in 3 quarters since. The position peaked at $2K in Q2 2021. 112 funds tracked by Wall St. Rank hold PRVB as of Q4 2021.

  • Reilly Financial Advisors held 200 shares of Provention Bio, Inc. Common Stock worth $1K as of Q4 2021.
  • Provention Bio, Inc. Common Stock was a new Reilly Financial Advisors position in Q4 2021.
  • Provention Bio, Inc. Common Stock made up ﹤0.01% of Reilly Financial Advisors's portfolio in Q4 2021, its #1111 holding.
  • Reilly Financial Advisors first reported a position in Provention Bio, Inc. Common Stock in Q1 2021 and has held it in 3 quarters since.
  • Reilly Financial Advisors's Provention Bio, Inc. Common Stock position peaked at $2K in Q2 2021.
  • 112 funds tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q4 2021.

Based on Reilly Financial Advisors's 13F filing for Q4 2021, filed 25 Jan 2022.